Merck

January 14, 2021January 14, 2021

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

News

Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of treatment, ... Read more

January 12, 2021January 12, 2021

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

News

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a ... Read more

November 10, 2020January 12, 2021

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

November 5, 2020November 5, 2020

First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer

News

The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with the checkpoint inhibitor Keytruda (pembrolizumab), in people with platinum-resistant ... Read more

October 6, 2020October 6, 2020

Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show

News

When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of ... Read more

September 24, 2020September 24, 2020

Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer

News

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

May 12, 2020January 12, 2021

FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This ... Read more

January 14, 2020February 21, 2020

FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status

News

The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination with ... Read more

December 13, 2019December 13, 2019

NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers

News

After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets ... Read more

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD ... Read more